FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of a cytolytic immune effector cell for the adoptive cell transfer; it can be used in medicine. The produced cell co-expresses the first chimeric antigen receptor (hereinafter – CAR) binding to CD19 and the second CAR binding to CD22 on the cell surface; it can be used for the effective therapy of malignant tumor that is characterized in the presence of cells that express CD19 and/or CD22.
EFFECT: obtaining a cell for the therapy of malignant tumors.
19 cl, 14 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| SIGNAL SYSTEM | 2015 |
|
RU2731638C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
